To assess the association of survivin expression with clinicopathological features and biochemical recurrence (BCR) after radical prostatectomy (RP) in a large multi-institutional cohort.
Objective
To assess the association of survivin expression with clinicopathological features and biochemical recurrence (BCR) after radical prostatectomy (RP) in a large multi-institutional cohort.
Methods
Survivin expression was evaluated by immunohistochemistry on a tissue microarray of RP cores from 3 117 patients. Survivin expression was considered altered when at least 10% of the tumour cells stained positive. The association of altered survivin expression with BCR was evaluated using Cox proportional hazards regression models.
Results
Survivin expression was altered in 1 330 patients (42.6%). Altered expression was associated with higher Gleason score on RP (P = 0.001), extracapsular extension (P = 0.019), seminal vesicle invasion (P < 0.001) and lymph node metastases (P = 0.009). The median (interquartile range) follow-up was 38 (21-66) months. Patients with altered survivin expression had a shorter BCR-free survival time than those with normal expression (5-year BCR-free survival estimates: 74.7 vs 79.0%; P = 0.008). Altered survivin expression did not retain its prognostic value, however, after adjustment for the effect of established clinicopathological factors (P = 0.73). Subgroup analyses also showed no independent prognostic value of survivin.
Introduction
With an estimated 220 800 new cases and 27 540 deaths in 2015, prostate cancer (PCa) is the most common non-cutaneous malignancy in the USA [1] . Radical prostatectomy (RP) with radiation therapy is the standard treatment for localized PCa, providing durable cancer control [2] ; however, almost one third of patients will experience biochemical recurrence (BCR) after these treatments. Early identification of these patients could allow adjuvant therapy which may lower the recurrence rate [3] . To provide a personalized approach, risk assessment and predictive tools have been developed [4] . These models mostly rely on clinicopathological features and have fallen short of optimum performance to date. Identification of new prognostic factors that could capture an individual's tumour potential could enhance current tools.
The survivin protein, a member of the inhibitors of apoptosis family, is implicated in the regulation of cell proliferation and apoptosis. Its expression has been extensively studied in various cancers, making it a promising biomarker and, increasingly, a target for therapy [5] . For example, in urothelial carcinoma of the bladder, survivin has been shown to predict cancer recurrence and survival after radical cystectomy [6, 7] . To date, only two small single-centre studies have reported a prognostic value for survivin in PCa [8, 9] ; therefore, as a part of the evaluation of any potential prognostic factor [10] , our objective was to determine the value of survivin as a prognostic marker for BCR in a large multi-institutional cohort of patients treated with RP.
Patients and Methods

Patient Selection and Data Collection
All participating sites obtained institutional review board approval for the study and provided institutional data-sharing agreements before the initiation of the study. The initial study cohort comprised 3 294 patients from eight European and North American centres, who underwent RP as treatment for PCa between 2000 and 2011, and who had tumour specimens available. We excluded from the analysis the patients with preoperative PSA levels >50 ng/mL, and those with missing preoperative PSA, surgical margin status, lymph node status and RP Gleason score data. A total of 3 117 patients were included in the analysis. No patient had metastases at the time of RP and no patient received preoperative radiotherapy, hormonal treatment or chemotherapy.
Pathological Evaluation and Immunochemistry
All surgical specimens were processed according to standard pathological procedures. Genito-urinary pathologists assigned the pathological stage and grade according to the 2007 American Joint Committee on Cancer TNM staging system and the International Society of Urological Pathology, respectively. Lymphatic tissue removed during RP was submitted for histological examination. Lymphovascular invasion was defined as the presence of tumour cells or tumour emboli within endothelial spaces without the underlying muscular wall being affected. Tumour cells in contact with the inked surface of the RP specimen defined positive surgical margins.
Survivin immunohistochemical staining was performed on tissue microarray slides in a single laboratory. Immunostaining was performed on the DAKO Autostainer (DAKO North America, Carpinteria, CA, USA) using an anti-survivin polyclonal rabbit antibody (Novus Biologicals, San Diego, CA, USA) at a dilution of 1:100. We used brightfield microscopy imaging coupled with advanced colour detection software (Automated Cellular Imaging System; Clarient, Holden, MA, USA) for staining assessment. No differentiation in the intensity or the localization of the staining was considered. Survivin expression was classified as 'altered' when >10% of the cells expressed survivin, as previously described [7, 8] . This 10% threshold was chosen based on a previous study, which showed that 10% reactivity was an indicator for PSA recurrence after surgery [8] .
Follow-Up
Follow-up was performed according to institutional protocols in agreement with local guidelines at the time. Generally, patients were seen postoperatively quarterly for the first year, semi-annually in the second year, and annually thereafter. BCR was defined as a PSA value >0.2 ng/mL on two consecutive visits. The date of BCR was determined according to the day of the first PSA value >0.2 ng/mL. None of the patients received radiotherapy or hormone treatment before BCR.
Statistical Analysis
The association of survivin expression with categorical variables was assessed using the chi-squared test. Differences in continuous variables were analysed using Kruskal-Wallis tests. The Kaplan-Meier method was used to generate BCRfree survival curves. Survival curves were compared using the log-rank test. Univariable and multivariable Cox regression models addressed the association of survivin with BCR after RP. All P values were two-sided, and statistical significance was defined as a P value <0.05. Statistical analyses were performed using STATA 11.0 statistical software (Stata Corp, College Station, TX, USA).
Results
Survivin expression was altered in 1 330 (42.6%) patients. The clinicopathological characteristics of the overall cohort and associations with survivin expression are shown in Table 1 . Altered survivin expression was associated with a higher Gleason score on the RP specimen (P = 0.001), extracapsular extension (P = 0.019), seminal vesicle invasion (P < 0.001) and lymph node metastases (P = 0.009).
Within a median (interquartile range) follow-up of 38 (21-66) months, 617 (19.8%) patients experienced BCR. Patients with altered survivin expression had shorter BCRfree survival times than those with normal expression of survivin (P = 0.008; Fig. 1 ). Table 2 summarizes the univariable and multivariable Cox regression analyses. In univariable analyses, preoperative PSA level, pathological Gleason sum, extracapsular extension, seminal vesicle invasion, surgical margin status, lymph node metastases and altered survivin expression were all significantly associated with BCR. In a model that adjusted for the effects of standard pathological features, survivin did not retain its association with BCR. In subgroup analyses, survivin was not found to have an association with BCR (Table 3) .
Discussion
We assessed the association of survivin expression with pathological features of PCa and its value in prognosticating BCR in a large multi-institutional RP cohort. We found that more than one third of the tumours in the studied cohort expressed survivin. This expression was associated with established features of biologically and clinically aggressive PCa, such as higher Gleason score on RP and lymph node metastasis. In various cancers, survivin expression has already been shown to be associated with adverse pathological features [6, 11, 12] . Indeed, survivin is known to regulate tumour cell proliferation [13] and apoptosis [5, 14] . Basic research has already accumulated evidence regarding the anti-apoptotic role of survivin in PCa cell lines [15] . Kishi et al. [16] assessed the levels of mRNA survivin in PCa specimens and reported that survivin expression was associated with adverse pathological features, such as higher pathological T stage, lymph node metastasis, vessel invasion, positive surgical margin and high Gleason score [16] . At the protein level, our results are consistent with previous studies that reported a significant association between survivin overexpression and high Gleason scores [8, 17] .
This association with several adverse pathological features in PCa is of great interest but does not ensure, however, that survivin has any prognostic value. Nevertheless, prediction of recurrence and metastases spread remains one crucial issue in PCa. In the present study, we showed that survivin expression was associated with BCR in univariable analysis; however, after adjusting for standard prognostic factors, survivin was no longer associated with impaired outcomes. These findings are similar to those previously observed in a smaller cohort [8] . In another study, Zhang et al. [9] distinguished nuclear and cytoplasmic expression of survivin in 68 and 65 patients, respectively. These patients were part of the RTOG 8 610 study cohort, and received either radiation therapy plus short-term androgen deprivation or radiation therapy alone.
Immunostaining was performed in PCa diagnostic needle biopsies or transurethral resections. In that study, only nuclear expression was independently associated with cancerspecific survival and overall survival. Surprisingly, however, nuclear expression did not predict distant metastasis. Although the number of patients was low, Zhang et al. demonstrated the potential need for subcellular discrimination of survivin expression, especially in PCa. Indeed, survivin may be responsible for different functions according to its expression in the cell: promotion of cell proliferation in the nucleus and control of cell survival in the cytoplasm [18, 19] . Several studies have already reported the prognostic value of cytoplasmic-to-nuclear ratio of survivin in breast cancer [5] . Nevertheless, both those studies and the present study highlight the limited value of easy and readily available immunohistochemical analysis of survivin expression in PCa.
New methods to assess survivin expression in malignancies have been proposed. In breast cancer, several studies have shown that survivin expression in circulating tumour cells is associated with adverse clinicopathological features and that it may have prognostic relevance regarding recurrence [20, 21] . In bladder cancer, the detection of the survivin protein and mRNA in the urine has also been proposed as a diagnostic and prognostic marker [6, 22] . Finally, survivin expression may also be assessed in the plasma and considered as a blood marker. Indeed, high serum survivin level at diagnosis has been reported as a prognostic factor for poor outcomes in pancreatic and ovarian carcinomas [23, 24] . Khan et al. [25] have already shown that, compared with healthy control subjects, levels of survivin expression in plasma exosomes were higher in patients with PCa. These new methods to assess survivin expression in urine, plasma or circulating tumour cells are promising, but warrant further investigations to identify any prognostic value in PCa.
The present study has several limitations, including those inherent to any retrospective study. Another limitation relates to the use of immunohistochemical techniques. These techniques may limit the reliability and reproducibility of the results because discrepancies exist regarding the antibodies, and technical and scoring protocols; however, tissue microarray, readily available staining protocols and automated scoring systems based on bright-field microscopy imaging coupled with advanced colour detection software were used to limit any variation at each step of the process. Accordingly, we did not discriminate between nuclear and cytoplasmic survivin expression. Finally, we only assessed early BCR in the present cohort with a short follow-up; however, we believe that, in PCa, early BCR should be considered a reliable endpoint associated with the risk of metastasis and cancer-specific mortality [26] .
In conclusion, altered survivin expression is associated with worse clinicopathological features in patients with PCa treated with RP; however, compared with standard postoperative features, altered survivin expression is not an independent predictor of BCR after RP. Assessment of survivin expression by standard immunostaining thus appears to be of limited value in clinical practice.
